National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Cancer (6)
- Cancer: Breast Cancer (2)
- (-) Cancer: Lung Cancer (12)
- Care Management (1)
- Case Study (1)
- Diagnostic Safety and Quality (3)
- Disabilities (1)
- Elderly (4)
- Health Status (2)
- Imaging (3)
- Medicare (1)
- Medication (1)
- Mortality (2)
- Outcomes (1)
- Palliative Care (2)
- Patient-Centered Outcomes Research (3)
- Patient Safety (1)
- Policy (1)
- Quality of Care (1)
- Registries (1)
- Research Methodologies (1)
- Respiratory Conditions (1)
- Screening (1)
- Shared Decision Making (2)
- Surgery (1)
- Treatments (2)
- U.S. Preventive Services Task Force (USPSTF) (1)
- Vaccination (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 12 of 12 Research Studies DisplayedBoffa D, Fernandez FG, Kim S
Surgically managed clinical stage iiia-clinical n2 lung cancer in the Society of Thoracic Surgeons Database.
The objective of this study was to characterize the management of clinical stage IIIA-N2 positive (cIIIA-N2) lung cancer in The Society of Thoracic Surgeons General Thoracic Surgery Database. Surgeons achieved excellent short- and long-term results treating predominantly lobectomy-amenable cIIIA-N2 lung cancer. However, prevalent overstaging and abstention from induction therapy suggested "overcoding" of false positives on imaging or variable compliance with current guidelines for cIIIA-N2 lung cancer.
AHRQ-funded; HS022279.
Citation: Boffa D, Fernandez FG, Kim S .
Surgically managed clinical stage iiia-clinical n2 lung cancer in the Society of Thoracic Surgeons Database.
Ann Thorac Surg 2017 Aug;104(2):395-403. doi: 10.1016/j.athoracsur.2017.02.031.
.
.
Keywords: Surgery, Cancer: Lung Cancer, Registries, Elderly, Outcomes
Schuler MS, Joyce NR, Huskamp HA
Medicare beneficiaries with advanced lung cancer experience diverse patterns of care from diagnosis to death.
Using Medicare claims data for patients diagnosed with extensive-stage small-cell lung cancer, the authors used latent class analysis to identify classes of people with different care patterns. The findings showed substantial heterogeneity in patterns of care for patients with advanced cancer, which should be accounted for in efforts to improve end-of-life care.
AHRQ-funded; HS022998.
Citation: Schuler MS, Joyce NR, Huskamp HA .
Medicare beneficiaries with advanced lung cancer experience diverse patterns of care from diagnosis to death.
Health Aff 2017 Jul;36(7):1193-200. doi: 10.1377/hlthaff.2017.0448..
Keywords: Cancer, Cancer: Lung Cancer, Care Management, Elderly, Medicare, Palliative Care
Meyer AND, Singh H
Calibrating how doctors think and seek information to minimise errors in diagnosis.
This editorial discusses a study by Sheringham et al., published in 2017 in BMJ Quality and Safety, and entitled “Variations in GPs’ decisions to investigate suspected lung cancer: a factorial experiment using multimedia vignettes” in which they used simulated patient vignettes to understand the role that patient characteristics (including demographics and symptomatology) play in physicians’ decisions to investigate for possible diagnosis of lung cancer.
AHRQ-funded; HS022087; HS023602.
Citation: Meyer AND, Singh H .
Calibrating how doctors think and seek information to minimise errors in diagnosis.
BMJ Qual Saf 2017 Jun;26(6):436-38. doi: 10.1136/bmjqs-2016-006071..
Keywords: Cancer: Lung Cancer, Shared Decision Making, Diagnostic Safety and Quality
Iyer AS, Bakitas M
Early palliative care in advanced illness: do right by mama.
This letter describes a case study where the doctor and the family decided not to do aggressive treatment on their mother in her 80’s with metastatic lung cancer and pneumonia. After describing the intubation procedure and the use of mechanical ventilation, the family decided that palliative care was the best option. The doctor emphasizes the use of palliative care as the best outcome for many terminally ill patients.
AHRQ-funded; HS023009; HS013852.
Citation: Iyer AS, Bakitas M .
Early palliative care in advanced illness: do right by mama.
JAMA Intern Med 2017 Jun;177(6):761-62. doi: 10.1001/jamainternmed.2017.0764.
.
.
Keywords: Cancer, Cancer: Lung Cancer, Case Study, Shared Decision Making, Elderly, Palliative Care, Patient-Centered Outcomes Research
Kao CJ, Wurz GT, Lin YC
Repurposing ospemifene for potentiating an antigen-specific immune response.
The overall objective of the present series of preclinical studies was to evaluate the immunomodulatory activity of ospemifene in combination with a peptide cancer vaccine. The authors concluded that, taken together, ospemifene's dose response and schedule-dependent immune modulating activity offers a method of tailoring and augmenting the efficacy of previously failed antigen-specific cancer vaccines for a wide range of malignancies.
AHRQ-funded; HS022236.
Citation: Kao CJ, Wurz GT, Lin YC .
Repurposing ospemifene for potentiating an antigen-specific immune response.
Menopause 2017 Apr;24(4):437-51. doi: 10.1097/gme.0000000000000776.
.
.
Keywords: Cancer: Breast Cancer, Cancer: Lung Cancer, Medication, Vaccination
Pruitt SL, Laccetti AL, Xuan L
Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer.
The researchers examined the prevalence and prognostic impact of a prior cancer diagnosis among patients with early-stage lung cancer. They found no difference in all-cause survival between patients with and without prior cancer. Lung cancer specific survival was improved among patients with prior cancer.
AHRQ-funded; HS022418.
Citation: Pruitt SL, Laccetti AL, Xuan L .
Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer.
Br J Cancer 2017 Mar 14;116(6):717-25. doi: 10.1038/bjc.2017.27.
.
.
Keywords: Research Methodologies, Cancer: Lung Cancer, Elderly, Patient-Centered Outcomes Research, Mortality
Roth JA, Goulart BH, Ravelo A
Survival gains from first-line systemic therapy in metastatic non-small cell lung cancer in the U.S., 1990-2015: progress and opportunities.
The objectives of this study were to quantify survival gains from 1990, when best supportive care only was standard, to 2015 and to estimate the impact of expanded use of new systemic therapies in clinically appropriate patients. By using simulation modeling to quantify metastatic non-small cell lung cancer survival gains from 1990-2015, the researchers estimated that the one-year survival proportion and mean per-patient survival increased by 14.1 percent and 4.2 months, respectively.
AHRQ-funded; HS022982.
Citation: Roth JA, Goulart BH, Ravelo A .
Survival gains from first-line systemic therapy in metastatic non-small cell lung cancer in the U.S., 1990-2015: progress and opportunities.
Oncologist 2017 Mar;22(3):304-10. doi: 10.1634/theoncologist.2016-0253.
.
.
Keywords: Treatments, Health Status, Cancer: Lung Cancer, Mortality, Patient-Centered Outcomes Research
Liu S, Mazur TR, Li H
A method to reconstruct and apply 3D primary fluence for treatment delivery verification.
In this study, a method is reported to perform IMRT and VMAT treatment delivery verification using 3D volumetric primary beam fluences reconstructed directly from planned beam parameters and treatment delivery records. The goals of this paper are to demonstrate that 1) 3D beam fluences can be reconstructed efficiently, and 2) quality assurance (QA) based on the reconstructed 3D fluences is capable of detecting additional treatment delivery errors, particularly for VMAT plans.
AHRQ-funded; HS022888.
Citation: Liu S, Mazur TR, Li H .
A method to reconstruct and apply 3D primary fluence for treatment delivery verification.
J Appl Clin Med Phys 2017 Jan;18(1):128-38. doi: 10.1002/acm2.12017.
.
.
Keywords: Patient Safety, Imaging, Cancer: Lung Cancer, Treatments, Quality of Care
Smieliauskas F, MacMahon H, Salgia R
Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening.
The researchers estimated the prevalence of capacity constraints in the radiologist workforce and resulting potential disparities in access to lung cancer screening. They found that scaling up lung cancer screening would increase imaging procedures by an average of 4% across Health Service Areas (HSAs). HSAs that were rural, with many eligible smokers, and disproportionately Hispanic or low-income smokers had significantly higher odds of facing capacity constraints.
AHRQ-funded; HS018535.
Citation: Smieliauskas F, MacMahon H, Salgia R .
Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening.
J Med Screen 2014 Dec;21(4):207-15. doi: 10.1177/0969141314548055..
Keywords: U.S. Preventive Services Task Force (USPSTF), Cancer, Cancer: Lung Cancer, Screening, Imaging
Gerber DE, Laccetti AL, Xuan L
Impact of prior cancer on eligibility for lung cancer clinical trials.
A prior cancer diagnosis often excludes patients from cancer clinical trials. Lung cancer patients were used to determine estimated impact on trial accrual. This study found that patients previously diagnosed with cancer were excluded in more than two-thirds of lung cancer trials. More research is needed to understand the basis of this policy.
AHRQ-funded; HS022418
Citation: Gerber DE, Laccetti AL, Xuan L .
Impact of prior cancer on eligibility for lung cancer clinical trials.
J Natl Cancer Inst. 2014 Nov;106(11). doi: 10.1093/jnci/dju302..
Keywords: Cancer: Lung Cancer, Policy, Cancer, Diagnostic Safety and Quality
Deppen SA, Blume JD, Kensinger CD
Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis.
The purpose of this study was to estimate the diagnostic accuracy of positron emission tomography (PET) combined with fludeoxyglucose F18 (FDG) for pulmonary modules suspicious for lung cancer in regions where infectious lung disease is endemic and compare the accuracy in regions where such disease is rare. It found that the accuracy of FDG-PET was extremely heterogeneous.
AHRQ-funded; HS021554.
Citation: Deppen SA, Blume JD, Kensinger CD .
Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis.
JAMA 2014 Sep 24;312(12):1227-36. doi: 10.1001/jama.2014.11488..
Keywords: Cancer, Cancer: Lung Cancer, Diagnostic Safety and Quality, Respiratory Conditions, Imaging
Davidoff AJ, Gardner LD, Zuckerman IH
AHRQ Author: Davidoff AJ
Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies.
The researchers implemented and validated a disability status (DS) measure in 4 cohorts of cancer patients. They found that the DS measure is a significant independent predictor of cancer-directed treatment, but unobserved factors continue to play a role in determining treatments.
AHRQ-authored.
Citation: Davidoff AJ, Gardner LD, Zuckerman IH .
Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies.
Med Care 2014 Jun;52(6):500-10. doi: 10.1097/mlr.0000000000000122.
.
.
Keywords: Cancer, Cancer: Breast Cancer, Disabilities, Health Status, Cancer: Lung Cancer